Effect of pioglitazone on the drivers of cardiovascular risk in type 2 diabetes

International Journal of Clinical Practice

Volumn 61, Issue 7, 2007, Pages 1160-1169

  Donnelly, R ^a,b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; HEMOGLOBIN A1C; INSULIN; LIPID; METFORMIN; PIOGLITAZONE; PLACEBO; RAMIPRIL; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TROGLITAZONE;

ADD ON THERAPY; ANKLE EDEMA; BODY FAT; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DIABETIC ANGIOPATHY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FLUID RETENTION; GLYCEMIC CONTROL; HEART FAILURE; HEMODILUTION; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN SENSITIVITY; INSULIN TREATMENT; LIPID METABOLISM; LIVER TOXICITY; METABOLIC REGULATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS FUNCTION; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; WEIGHT GAIN;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; MIDDLE AGED; RISK FACTORS; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 34250649805     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01396.x     Document Type: Review

References (48)

1. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005 366: 1279 89.
2. Proactive-results.com. PROactive Study: PROspective pioglitAzone Clinical Trial In macroVascular Events. http://www.proactive-results.com.2007 (accessed February, 2007).
3. Charbonnel B, Scheen A. Pioglitazone in triple oral therapy: long-term glycemic results from PROactive. Diabetes 2006 55: A106.
4. Massi-Benedetti M, Scheen A, Charbonnel B. Pioglitazone delays the need for permanent insulin use: results from PROactive. Diabetes 2006 55: A124.
5. Scheen A, Charbonnel B, on behalf of The PROactive Investigators. Reduced insulin requirements and improved glycemic control with pioglitazone in insulin-treated patients with type 2 diabetes: results from PROactive. Diabetes 2006 55 (Suppl. 1 A134.
6. Tan MH, Baksi A, Krahulec B et al. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care 2005 28: 544 50.
7. Schernthaner G, Matthews DR, Charbonnel B et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004 89: 6068 76.
8. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006 355: 2427 43.
9. Einhorn D, Rendell M, Rosenzweig J et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000 22: 1395 409.
10. Charbonnel B, Schernthaner G, Brunetti P et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005 48: 1093 104.
11. Charbonnel B, Matthews DR, Schernthaner G et al. A long-term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med 2004 22: 399 405.
12. Perriello G, Pampanelli S, Di Pietro C et al. Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with type 2 diabetes. Diabet Med 2006 23: 246 52.
13. Davidson JA, Perez A, Zhang J The Pioglitazone 343 Study Group. Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study. Diabetes Obes Metab 2006 8: 164 74.
14. Mattoo V, Eckland D, Widel M et al. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study. Clin Ther 2005 27: 554 67.
15. Rosenstock J. Improved insulin sensitivity and beta cell responsivity suggested by HOMA analysis of pioglitazone therapy. Diabetologia 2000 43 (Suppl. 1 A738.
16. Wallace TM, Levy JC, Matthews DR. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. Diabet Med 2004 21: 568 76.
17. Xiang AH, Peters RK, Kjos SL et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006 55: 517 22.
18. The DREAM Trial Investigators. Effect of Rosiglitazone on the Frequency of Diabetes in Patients with Impaired Glucose Tolerance or Impaired Fasting Glucose: a Randomised Controlled Trial. Lancet 2006 368: 1096 105.
19. Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 2002 25: 517 23.
20. Kipnes MS, Krosnick A, Rendell MS et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001 111: 10 7.
21. Berhanu P, Kipnes MS, Khan MA et al. Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy. Diab Vasc Dis Res 2006 3: 39 44.
22. Derosa G, Cicero AF, Gaddi A et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther 2004 26: 744 54.
23. Derosa G, D'Angelo A, Ragonesi PD et al. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther 2006 31: 375 83.
24. Goldberg RB, Kendall DM, Deeg MA et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005 28: 1547 54.
25. Hanefeld M, Brunetti P, Schernthaner GH et al. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004 27: 141 7.
26. Matthews DR, Charbonnel BH, Hanefeld M et al. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev 2005 21: 167 74.
27. Tan MH, Johns D, Strand J et al. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with type 2 diabetes. Diabet Med 2004 21: 859 66.
28. Gazi IF, Tsimihodimos V, Tselepis AD et al. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther 2007 7: 53 72.
29. Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004 164: 2097 104.
30. Waugh J, Keating GM, Plosker GL et al. Pioglitazone: a review of its use in type 2 diabetes mellitus. Drugs 2006 66: 85 109.
31. Miyazaki Y, Mahankali A, Matsuda M et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002 87: 2784 91.
32. Smith SR, De Jonge L, Volaufova J et al. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism 2005 54: 24 32.
33. Basu A, Rizza R, Joyner M. Increased body water content is the major cause of weight gain with pioglitazone despite improved hemodynamic parameters in type 2 diabetes. Presented at the European Association for the Study of Diabetes 41st Annual Meeting. Athens, 10-5 September, 2005.
34. Khalili P, Nilsson PM, Nilsson JA, Berglund G. Smoking as a modifier of the systolic blood pressure-induced risk of cardiovascular events and mortality: a population-based prospective study of middle-aged men. J Hypertens 2002 20: 1759 64.
35. Saadeddin SM, Habbab MA, Ferns GA. Markers of inflammation and coronary artery disease. Med Sci Monit 2002 8: RA5 12.
36. Watkins LO. Epidemiology and burden of cardiovascular disease. Clin Cardiol 2004 27: III2 6.
37. Basu A, Jensen M, McCann F et al. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care 2006 29: 510 4.
38. Martens FM, Visseren FL, Lemay J et al. Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002 62: 1463 80.
39. Shimizu H, Oh-I S, Tsuchiya T et al. Pioglitazone increases circulating adiponectin levels and subsequently reduces TNF-alpha levels in type 2 diabetic patients: a randomized study. Diabet Med 2006 23: 253 7.
40. Szapary PO, Bloedon LT, Samaha FF et al. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol 2006 26: 182 8.
41. Vasudevan AR, Balasubramanyam A. Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability. Diabetes Technol Ther 2004 6: 850 63.
42. Belcher G, Lambert C, Edwards G et al. Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes. Diabetes Res Clin Pract 2005 70: 53 62.
43. Takeda UK Ltd. ACTOS Summary of Product Characteristics. Takeda UK Ltd, 2007.
44. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000 321: 405 12.
45. Robins SJ, Collins D, Wittes JT et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001 285: 1585 91.
46. Rubins HB, Robins SJ, Collins D et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002 162: 2597 604.
47. Adler AI, Stratton IM, Neil HA et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000 321: 412 9.
48. Gæde P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003 348: 383 93.